Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinoma
Autor(a) principal: | |
---|---|
Data de Publicação: | 2004 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Revista Brasileira de Cancerologia (Online) |
Texto Completo: | https://rbc.inca.gov.br/index.php/revista/article/view/2024 |
Resumo: | Technetium-99m-methoxyisobutil isonitrila (99mTc-MIBI) has been introduced as a tumor-seeking agent in the past few years. The present study has evaluated the role of 99mTc-MIBI whole body scan (WBS) in localizing metastatic lesions by assessing sensitivity and specificity in comparison with 131I scan and serum thyroglobulin measurement. Eighty-nine thyroidectomized patients due to differentiated thyroid cancer were enrolled. Early (20 minutes) and delayed (6 and 24 hours) whole body images were obtained after 99mTc-MIBI injection. Tg measurements were obtained during thyroid hormone reposition and 4 weeks after hormone discontinuation, 131I scans were performed after low diagnostic or high ablative/therapeutic dose. These methods were used as standard to evaluate the presence of residual or metastatic thyroid cancer. The patients with 99mTc-MIBI scan positive and 131I negative scan underwent chest x-ray, computed tomography (CT) or magnetic resonance imaging (MRI). In the group with 131I negative scan (34/89), 23 patients presented 99mTc-MIBI WBS negative and 11 patients were discordant (specificity: 67,6%), and 22 patients had 99mTc-MIBI WBS and 131I scan positive; while the total of 131I scans positive was 55 (sensitivity: 40,0%). Eleven patients had 131I scan negative and 99mTc-MIBI WBS positive; seven of those proved to be true positive. Although 99mTc-MIBI has low sensitivity on detection of tumor recurrence, it may have a role as a supplementary tool to thyroglobulin measurements and 131I scans. |
id |
INCA-1_f8dc6f43ff1511c03acd66e7501bf718 |
---|---|
oai_identifier_str |
oai:rbc.inca.gov.br:article/2024 |
network_acronym_str |
INCA-1 |
network_name_str |
Revista Brasileira de Cancerologia (Online) |
repository_id_str |
|
spelling |
Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinomaTecnécio-99M-MIBI no acompanhamento de carcinoma diferenciado de tireóideNeoplasias da tireóideCarcinomaCintilografiaTireoglobulinaMIBIThyroid neoplasmsCarcinomaRadionuclide imagingThyroglobulinMIBITechnetium-99m-methoxyisobutil isonitrila (99mTc-MIBI) has been introduced as a tumor-seeking agent in the past few years. The present study has evaluated the role of 99mTc-MIBI whole body scan (WBS) in localizing metastatic lesions by assessing sensitivity and specificity in comparison with 131I scan and serum thyroglobulin measurement. Eighty-nine thyroidectomized patients due to differentiated thyroid cancer were enrolled. Early (20 minutes) and delayed (6 and 24 hours) whole body images were obtained after 99mTc-MIBI injection. Tg measurements were obtained during thyroid hormone reposition and 4 weeks after hormone discontinuation, 131I scans were performed after low diagnostic or high ablative/therapeutic dose. These methods were used as standard to evaluate the presence of residual or metastatic thyroid cancer. The patients with 99mTc-MIBI scan positive and 131I negative scan underwent chest x-ray, computed tomography (CT) or magnetic resonance imaging (MRI). In the group with 131I negative scan (34/89), 23 patients presented 99mTc-MIBI WBS negative and 11 patients were discordant (specificity: 67,6%), and 22 patients had 99mTc-MIBI WBS and 131I scan positive; while the total of 131I scans positive was 55 (sensitivity: 40,0%). Eleven patients had 131I scan negative and 99mTc-MIBI WBS positive; seven of those proved to be true positive. Although 99mTc-MIBI has low sensitivity on detection of tumor recurrence, it may have a role as a supplementary tool to thyroglobulin measurements and 131I scans.Tecnécio-99m-metoxiisobutil isonitrila (99mTc-MIBI) foi, recentemente, introduzido como fármaco marcador-tumoral. Este estudo avalia o papel da cintilografia com 99mTc-MIBI na localização de lesões metastáticas através da análise de sua sensibilidade e especificidade, em comparação com rastreamento com 131I e níveis séricos de tireoglobulina. Foram estudados oitenta e nove pacientes tireoidectomizados por câncer diferenciado de tireóide. Foram adquiridas imagens de corpo inteiro precoces (20 minutos) e tardias (6 e 24 horas) após injeção de 99mTc- MIBI. Foram determinados os níveis séricos de tireoglobulina durante tratamento com hormônio tireoideano e 4 semanas após sua suspensão; rastreamento com 131I foi realizado após dose diagnóstica ou terapêutica/ablativa. Os pacientes que apresentaram resultados discordantes, foram submetidos a confirmação diagnóstica por tomografia computadorizada ou ressonância magnética. No grupo com rastreamento com 131I negativo (34/89), 23 pacientes apresentaram cintilografia com 99mTc-MIBI negativa e 11 pacientes tiveram resultado discordante (especificidade: 67,6%); 22 pacientes apresentaram cintilografia com 99mTc-MIBI e rastreamento com 131I positivas; enquanto o total de rastreamento com 131I positivos foi 55(sensibilidade: 40,0%). Onze pacientes apresentaram rastreamento com 131I e cintilografia com 99mTc-MIBI positiva; 7 destes pacientes foram comprovados como verdadeiros positivos; e quando associados os valores de tireoglobulina e os resultados encontrados pela cintilografia com 99mTc-MIBI, a sensibilidade passa a ser de 66,7% e a especificidade de 86,7%. Embora o 99mTc-MIBI apresente baixa sensibilidade na detecção de doença em atividade, o 99mTc-MIBI pode desempenhar papel importante como um método complementar aos valores de tireoglobulina e rastreamento com 131I.INCA2004-09-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos, Avaliado pelos paresapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/202410.32635/2176-9745.RBC.2004v50n3.2024Revista Brasileira de Cancerologia; Vol. 50 No. 3 (2004): July/Aug./Sept; 203-210Revista Brasileira de Cancerologia; Vol. 50 Núm. 3 (2004): jul./ago/sept.; 203-210Revista Brasileira de Cancerologia; v. 50 n. 3 (2004): jul./ago.set.; 203-2102176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporhttps://rbc.inca.gov.br/index.php/revista/article/view/2024/1244Machado, Luiz S.Pedras, Dauro S.V.Antonucci, Jane B.Corbo, Rossanainfo:eu-repo/semantics/openAccess2021-11-29T20:32:45Zoai:rbc.inca.gov.br:article/2024Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T20:32:45Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false |
dc.title.none.fl_str_mv |
Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinoma Tecnécio-99M-MIBI no acompanhamento de carcinoma diferenciado de tireóide |
title |
Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinoma |
spellingShingle |
Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinoma Machado, Luiz S. Neoplasias da tireóide Carcinoma Cintilografia Tireoglobulina MIBI Thyroid neoplasms Carcinoma Radionuclide imaging Thyroglobulin MIBI |
title_short |
Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinoma |
title_full |
Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinoma |
title_fullStr |
Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinoma |
title_full_unstemmed |
Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinoma |
title_sort |
Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinoma |
author |
Machado, Luiz S. |
author_facet |
Machado, Luiz S. Pedras, Dauro S.V. Antonucci, Jane B. Corbo, Rossana |
author_role |
author |
author2 |
Pedras, Dauro S.V. Antonucci, Jane B. Corbo, Rossana |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Machado, Luiz S. Pedras, Dauro S.V. Antonucci, Jane B. Corbo, Rossana |
dc.subject.por.fl_str_mv |
Neoplasias da tireóide Carcinoma Cintilografia Tireoglobulina MIBI Thyroid neoplasms Carcinoma Radionuclide imaging Thyroglobulin MIBI |
topic |
Neoplasias da tireóide Carcinoma Cintilografia Tireoglobulina MIBI Thyroid neoplasms Carcinoma Radionuclide imaging Thyroglobulin MIBI |
description |
Technetium-99m-methoxyisobutil isonitrila (99mTc-MIBI) has been introduced as a tumor-seeking agent in the past few years. The present study has evaluated the role of 99mTc-MIBI whole body scan (WBS) in localizing metastatic lesions by assessing sensitivity and specificity in comparison with 131I scan and serum thyroglobulin measurement. Eighty-nine thyroidectomized patients due to differentiated thyroid cancer were enrolled. Early (20 minutes) and delayed (6 and 24 hours) whole body images were obtained after 99mTc-MIBI injection. Tg measurements were obtained during thyroid hormone reposition and 4 weeks after hormone discontinuation, 131I scans were performed after low diagnostic or high ablative/therapeutic dose. These methods were used as standard to evaluate the presence of residual or metastatic thyroid cancer. The patients with 99mTc-MIBI scan positive and 131I negative scan underwent chest x-ray, computed tomography (CT) or magnetic resonance imaging (MRI). In the group with 131I negative scan (34/89), 23 patients presented 99mTc-MIBI WBS negative and 11 patients were discordant (specificity: 67,6%), and 22 patients had 99mTc-MIBI WBS and 131I scan positive; while the total of 131I scans positive was 55 (sensitivity: 40,0%). Eleven patients had 131I scan negative and 99mTc-MIBI WBS positive; seven of those proved to be true positive. Although 99mTc-MIBI has low sensitivity on detection of tumor recurrence, it may have a role as a supplementary tool to thyroglobulin measurements and 131I scans. |
publishDate |
2004 |
dc.date.none.fl_str_mv |
2004-09-30 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Artigos, Avaliado pelos pares |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rbc.inca.gov.br/index.php/revista/article/view/2024 10.32635/2176-9745.RBC.2004v50n3.2024 |
url |
https://rbc.inca.gov.br/index.php/revista/article/view/2024 |
identifier_str_mv |
10.32635/2176-9745.RBC.2004v50n3.2024 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rbc.inca.gov.br/index.php/revista/article/view/2024/1244 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
INCA |
publisher.none.fl_str_mv |
INCA |
dc.source.none.fl_str_mv |
Revista Brasileira de Cancerologia; Vol. 50 No. 3 (2004): July/Aug./Sept; 203-210 Revista Brasileira de Cancerologia; Vol. 50 Núm. 3 (2004): jul./ago/sept.; 203-210 Revista Brasileira de Cancerologia; v. 50 n. 3 (2004): jul./ago.set.; 203-210 2176-9745 reponame:Revista Brasileira de Cancerologia (Online) instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) instacron:INCA |
instname_str |
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
instacron_str |
INCA |
institution |
INCA |
reponame_str |
Revista Brasileira de Cancerologia (Online) |
collection |
Revista Brasileira de Cancerologia (Online) |
repository.name.fl_str_mv |
Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
repository.mail.fl_str_mv |
rbc@inca.gov.br |
_version_ |
1797042248921120768 |